

Hideho Okada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7217730/publications.pdf>

Version: 2024-02-01

132
papers

11,217
citations

34016

52
h-index

32761

100
g-index

138
all docs

138
docs citations

138
times ranked

14264
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. <i>Neuro-Oncology</i> , 2022, 24, 259-272.	0.6	6
2	Immunomodulatory roles of myeloid cells in gliomas. , 2022, , 109-125.		0
3	The current landscape of immunotherapy for pediatric brain tumors. <i>Nature Cancer</i> , 2022, 3, 11-24.	5.7	21
4	Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	32
5	The immunology of low-grade gliomas. <i>Neurosurgical Focus</i> , 2022, 52, E2.	1.0	20
6	Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. , 2022, 10, e004644.		14
7	The future of cancer immunotherapy for brain tumors: a collaborative workshop. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	7
8	IMMU-14. SynNotch chimeric antigen receptor (CAR) T-cells as a potential treatment for diffuse intrinsic pontine glioma (DIPG)/diffuse midline glioma (DMG). <i>Neuro-Oncology</i> , 2022, 24, i84-i84.	0.6	0
9	Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219.	1.4	5
10	Current Advances in Immunotherapy for Glioblastoma. <i>Current Oncology Reports</i> , 2021, 23, 21.	1.8	26
11	SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	215
12	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. , 2021, 9, e002181.		42
13	IFN- γ - and IL-17-producing CD8 ⁺ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity. , 2021, 9, e002426.		8
14	The evolution of alternative splicing in glioblastoma under therapy. <i>Genome Biology</i> , 2021, 22, 48.	3.8	23
15	Assessing Oximetry Response to Chimeric Antigen Receptor T-cell Therapy against Glioma with 19F MRI in a Murine Model. <i>Radiology Imaging Cancer</i> , 2021, 3, e200062.	0.7	7
16	Zika virus oncolytic activity requires CD8 ⁺ T cells and is boosted by immune checkpoint blockade. <i>JCI Insight</i> , 2021, 6, .	2.3	46
17	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	0.6	59
18	Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine- 19 MRI detection. <i>Magnetic Resonance in Medicine</i> , 2020, 83, 974-987.	1.9	40

#	ARTICLE	IF	CITATIONS
19	Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. <i>Journal of Neuro-Oncology</i> , 2020, 146, 71-78.	1.4	5
20	The current state of immunotherapy for primary and secondary brain tumors: similarities and differences. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1231-1245.	0.6	13
21	The Great Debate at "Immunotherapy Bridge"™, Naples, December 5, 2019. , 2020, 8, e000921.		3
22	T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment. <i>Journal of Neuro-Oncology</i> , 2020, 147, 281-295.	1.4	32
23	Introduction to immunotherapy for brain tumor patients: challenges and future perspectives. <i>Neuro-Oncology Practice</i> , 2020, 7, 465-476.	1.0	10
24	Tumor antigens in glioma. <i>Seminars in Immunology</i> , 2020, 47, 101385.	2.7	34
25	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. <i>Nature Communications</i> , 2020, 11, 524.	5.8	29
26	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. <i>Journal of Clinical Investigation</i> , 2020, 130, 6325-6337.	3.9	70
27	THER-05. GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION. <i>Neuro-Oncology</i> , 2020, 22, iii472-iii472.	0.6	0
28	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268.	2.5	45
29	IMMU-18. TARGETING H3.3 K27M MUTATION AS A SHARED NEOANTIGEN IN HLA-A*0201+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS " DEVELOPMENT OF A NOVEL MASS CYTOMETRY-BASED MONITORING OF VACCINE-REACTIVE, EPITOPE-SPECIFIC CD8+ T CELL RESPONSES. <i>Neuro-Oncology</i> , 2019, 21, ii96-ii96.	0.6	1
30	The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. , 2019, 7, 58.		109
31	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. <i>World Neurosurgery</i> , 2019, 124, 397-409.	0.7	19
32	RDNA-09. RADIATION PRIMES SB28 GLIOBLASTOMA FOR RESPONSE TO TGF β 2 AND PD-L1 NEUTRALIZING ANTIBODIES. <i>Neuro-Oncology</i> , 2019, 21, vi208-vi208.	0.6	2
33	PDCT-17 (LTBK-11). PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi284-vi285.	0.6	1
34	IMMU-11. SPATIOTEMPORAL IMMUNOGENOMIC ANALYSIS OF THE T-CELL REPERTOIRE IN IDH-MUTANT LOWER GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi121-vi121.	0.6	0
35	IMMU-38. CRISPR BASED GENOME EDITING OF HUMAN T CELLS TO TARGET H3.3K27M MUTATION IN GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi127-vi127.	0.6	0
36	IMMU-45. CAR-T TREATMENT OF NOVEL MOUSE MODEL OF EGFRVIII+ GBM MIRRORS CLINICAL TRIAL OUTCOMES AND PROVIDES A SYNGENEIC PLATFORM FOR THE INVESTIGATION OF CAR-T MECHANISMS OF ACTION. <i>Neuro-Oncology</i> , 2019, 21, vi128-vi129.	0.6	0

#	ARTICLE	IF	CITATIONS
37	IMMU-21. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi123-vi123.	0.6	0
38	IMMU-30. UTILIZING A NOVEL MASS CYTOMETRY-BASED IMMUNOMONITORING PLATFORM FOR THE CHARACTERIZATION OF VACCINE-REACTIVE, EPITOPE-SPECIFIC CD8+ T-CELLS IN HLA-A*0201+ PATIENTS WITH K27M+ DIFFUSE MIDLINE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi125-vi125.	0.6	0
39	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	13.7	637
40	Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. <i>Oncolimmunology</i> , 2018, 7, e1391972.	2.1	42
41	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. <i>Journal of Experimental Medicine</i> , 2018, 215, 141-157.	4.2	186
42	IMMU-57. SEQUENTIAL TWO-RECEPTOR PRIMING CAR SYSTEM TO OVERCOME HETEROGENEOUS ANTIGEN EXPRESSION. <i>Neuro-Oncology</i> , 2018, 20, vi134-vi134.	0.6	0
43	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. <i>Oncolimmunology</i> , 2018, 7, e1501137.	2.1	120
44	Immunotherapy Response Assessment in Neuro-Oncology (iRANO). , 2018, , 761-766.		1
45	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145.	2.5	41
46	Immunotherapy of Primary Brain Tumors: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 5198-5205.	3.2	66
47	Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 3062.	2.2	49
48	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. <i>JCI Insight</i> , 2018, 3, .	2.3	21
49	Is the immune response a friend or foe for viral therapy of glioma?. <i>Neuro-Oncology</i> , 2017, 19, 882-883.	0.6	2
50	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	1,116
51	Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 155-166.	0.5	8
52	Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. <i>Genome Biology</i> , 2017, 18, 234.	3.8	448
53	Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model. <i>Scientific Reports</i> , 2017, 7, 17748.	1.6	29
54	IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES. <i>Neuro-Oncology</i> , 2017, 19, vi124-vi124.	0.6	0

#	ARTICLE	IF	CITATIONS
55	ATIM-11. PILOT STUDY OF TUMOR LYSATE VACCINE AND IMIQUIMOD IN ADULTS WITH WHO GRADE II GLIOMAS. <i>Neuro-Oncology</i> , 2017, 19, vi28-vi28.	0.6	0
56	IMMU-42. ONO-AE3-208 PROMOTES ANTI-TUMOR IMMUNE ACTIVITY AND SURVIVAL IN GLIOMA MODELS. <i>Neuro-Oncology</i> , 2017, 19, vi122-vi122.	0.6	0
57	Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. <i>Journal of Clinical Investigation</i> , 2017, 127, 1425-1437.	3.9	334
58	IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. <i>Neuro-Oncology</i> , 2016, 18, 1402-1412.	0.6	126
59	Detection of inflammatory cell function using ¹³ C magnetic resonance spectroscopy of hyperpolarized [6- ¹³ C]-arginine. <i>Scientific Reports</i> , 2016, 6, 31397.	1.6	24
60	Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. <i>Journal of Neuro-Oncology</i> , 2016, 130, 517-527.	1.4	49
61	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 543-552.	1.4	90
62	Cellular immunotherapy for malignant gliomas. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1265-1275.	1.4	37
63	Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1157-1168.	0.6	69
64	Principles of immunology and its nuances in the central nervous system: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii3-vii8.	0.6	28
65	Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. <i>Science Translational Medicine</i> , 2015, 7, 275ra22.	5.8	369
66	Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 549-554.	1.0	26
67	Induction of Robust Type-I CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. <i>Clinical Cancer Research</i> , 2015, 21, 286-294.	3.2	92
68	Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. <i>Oncolmmunology</i> , 2015, 4, e1008347.	2.1	91
69	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
70	Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. <i>Oncolmmunology</i> , 2015, 4, e1047581.	2.1	12
71	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
72	STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2014, 2, 1199-1208.	1.6	185

#	ARTICLE	IF	CITATIONS
73	Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas. <i>Journal of Clinical Oncology</i> , 2014, 32, 2050-2058.	0.8	167
74	Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 847-857.	2.0	82
75	GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor- β . <i>Cancer Research</i> , 2013, 73, 6413-6423.	0.4	169
76	Immune-Checkpoint Blockade and Active Immunotherapy for Glioma. <i>Cancers</i> , 2013, 5, 1379-1412.	1.7	33
77	Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. , 2013, 1, 21.		85
78	Premetastatic soil and prevention of breast cancer brain metastasis. <i>Neuro-Oncology</i> , 2013, 15, 891-903.	0.6	76
79	LOH in the HLA Class I Region at 6p21 Is Associated with Shorter Survival in Newly Diagnosed Adult Glioblastoma. <i>Clinical Cancer Research</i> , 2013, 19, 1816-1826.	3.2	70
80	Vaccines Targeting Tumor Blood Vessel Antigens Promote CD8+ T Cell-Dependent Tumor Eradication or Dormancy in HLA-A2 Transgenic Mice. <i>Journal of Immunology</i> , 2012, 188, 1782-1788.	0.4	44
81	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor β 2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. <i>Cytotherapy</i> , 2012, 14, 733-742.	0.3	56
82	Myeloid-derived Suppressor Cells (MDSCs) in Gliomas and Glioma-Development. <i>Immunological Investigations</i> , 2012, 41, 658-679.	1.0	56
83	Type 17 T-cells in Central Nervous System Autoimmunity and Tumors. <i>Journal of Clinical Immunology</i> , 2012, 32, 802-808.	2.0	26
84	Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 789-801.	2.0	53
85	MicroRNAs and STAT interplay. <i>Seminars in Cancer Biology</i> , 2012, 22, 70-75.	4.3	94
86	Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. <i>Journal of Neuro-Oncology</i> , 2011, 104, 83-92.	1.4	152
87	Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?. <i>Immunologic Research</i> , 2011, 50, 235-247.	1.3	28
88	COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2011, 71, 2664-2674.	0.4	331
89	Do we need novel radiologic response criteria for brain tumor immunotherapy?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 619-622.	1.4	22
90	Induction of CD8 ⁺ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With β -Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 330-336.	0.8	519

#	ARTICLE	IF	CITATIONS
91	Absence of Stat1 in donor CD4+ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 2554-2569.	3.9	72
92	Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN- α and IFN- β dependent manners. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1401-1409.	2.0	83
93	Role of Type 1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans. <i>Clinical Cancer Research</i> , 2010, 16, 3409-3419.	3.2	80
94	miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2010, 8, 17.	1.8	67
95	MicroRNAs in immune regulation—Opportunities for cancer immunotherapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1256-1261.	1.2	78
96	Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumors. <i>Seminars in Immunology</i> , 2010, 22, 173-182.	2.7	62
97	Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells—Significant Roles of CXCL10. <i>Cancer Research</i> , 2009, 69, 1587-1595.	0.4	99
98	Systemic Inhibition of Transforming Growth Factor- β in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines. <i>Clinical Cancer Research</i> , 2009, 15, 6551-6559.	3.2	106
99	Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 10746-10751.	3.3	161
100	Brain Tumor Immunotherapy with Type-1 Polarizing Strategies. <i>Annals of the New York Academy of Sciences</i> , 2009, 1174, 18-23.	1.8	34
101	Immunotherapeutic Approaches for Glioma. <i>Critical Reviews in Immunology</i> , 2009, 29, 1-42.	1.0	132
102	Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 88, 245-250.	1.4	77
103	Inhibition of STAT3 Promotes the Efficacy of Adoptive Transfer Therapy Using Type-1 CTLs by Modulation of the Immunological Microenvironment in a Murine Intracranial Glioma. <i>Journal of Immunology</i> , 2008, 180, 2089-2098.	0.4	99
104	Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo. <i>Journal of Immunology</i> , 2008, 181, 104-108.	0.4	28
105	Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell-Based Therapeutics. <i>Clinical Cancer Research</i> , 2007, 13, 566-575.	3.2	146
106	Helper Function of Memory CD8+ T Cells: Heterologous CD8+ T Cells Support the Induction of Therapeutic Cancer Immunity. <i>Cancer Research</i> , 2007, 67, 10012-10018.	0.4	27
107	Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors. <i>Cancer Research</i> , 2007, 67, 6451-6458.	0.4	60
108	Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. <i>Journal of Translational Medicine</i> , 2007, 5, 10.	1.8	161

#	ARTICLE	IF	CITATIONS
109	Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. <i>Journal of Translational Medicine</i> , 2007, 5, 67.	1.8	112
110	Identification of Interleukin-13 Receptor $\beta 2$ Peptide Analogues Capable of Inducing Improved Antiglioma CTL Responses. <i>Cancer Research</i> , 2006, 66, 5883-5891.	0.4	59
111	Adoptive Transfer of Type 1 CTL Mediates Effective Anti-CNS Tumor Response: Critical Roles of IFN-Inducible Protein-10. <i>Cancer Research</i> , 2006, 66, 4478-4487.	0.4	84
112	Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. <i>Cancer Gene Therapy</i> , 2005, 12, 757-768.	2.2	98
113	IL-4-Transfected Tumor Cell Vaccines Activate Tumor-Infiltrating Dendritic Cells and Promote Type-1 Immunity. <i>Journal of Immunology</i> , 2005, 174, 7194-7201.	0.4	34
114	Delivery of Dendritic Cells Engineered to Secrete IFN- β into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways. <i>Journal of Immunology</i> , 2005, 175, 2730-2740.	0.4	54
115	The Characterization of Tumor Apoptosis after Experimental Radiosurgery. <i>Stereotactic and Functional Neurosurgery</i> , 2005, 83, 17-24.	0.8	33
116	EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines. <i>Neoplasia</i> , 2005, 7, 717-722.	2.3	126
117	Biologic Therapy for Brain Cancers - Based on Cellular and Immunobiology. <i>Yonsei Medical Journal</i> , 2004, 45, S68.	0.9	0
118	Cytokine gene therapy for malignant glioma. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1609-1620.	1.4	53
119	Delivery of Interferon- β Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines. <i>Cancer Research</i> , 2004, 64, 5830-5838.	0.4	40
120	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 13-20.	1.4	16
121	Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. <i>Journal of Neuro-Oncology</i> , 2003, 64, 13-20.	1.4	74
122	Expression of a soluble transforming growth factor- $\beta 2$ (TGF $\beta 2$) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. <i>Journal of Neuro-Oncology</i> , 2003, 64, 63-69.	1.4	23
123	Effective induction of antiglioma cytotoxic T cells by coadministration of interferon- $\beta 2$ gene vector and dendritic cells. <i>Cancer Gene Therapy</i> , 2003, 10, 549-558.	2.2	29
124	Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. <i>Cancer Research</i> , 2003, 63, 6378-86.	0.4	105
125	Gene Therapy and Biologic Therapy with Interleukin-4. <i>Current Gene Therapy</i> , 2002, 2, 437-450.	0.9	22
126	7-Hydroxystaurosporine-induced Apoptosis in 9L Glioma Cells Provides an Effective Antigen Source for Dendritic Cells and Yields a Potent Vaccine Strategy in an Intracranial Glioma Model. <i>Neurosurgery</i> , 2002, 50, 1327-1335.	0.6	26

#	ARTICLE	IF	CITATIONS
127	Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. <i>Cancer Research</i> , 2002, 62, 2583-91.	0.4	58
128	Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. <i>Clinical Cancer Research</i> , 2002, 8, 2851-5.	3.2	99
129	Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. <i>Cancer Gene Therapy</i> , 2000, 7, 486-494.	2.2	13
130	Exploitation of immune mechanisms in the treatment of central nervous system cancer. <i>Seminars in Pediatric Neurology</i> , 2000, 7, 131-143.	1.0	24
131	Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. , 1998, 78, 196-201.		95
132	Suppression of CD44 expression decreases migration and invasion of human glioma cells. , 1996, 66, 255-260.		66